Navigation Links
Ardea Biosciences Reports Positive Phase 2a Results for Lead HIV Candidate, RDEA806, Demonstrating up to 2.0 Log Reduction in Plasma Viral Load
Date:3/17/2008

mitogen-activated ERK kinase (MEK) inhibitor, RDEA119, is in a Phase 1 study in advanced cancer patients and is being investigated for the treatment of inflammatory diseases. Ardea also is developing a next-generation NNRTI for HIV and a next-generation MEK inhibitor for both cancer and inflammatory diseases.

Statements contained in this press release regarding matters that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Such statements include, but are not limited to, statements regarding: Ardea's goals, including the expected properties and benefits of RDEA806 and RDEA119 and its other compounds and the results of clinical and other studies. Risks that contribute to the uncertain nature of the forward-looking statements include: risks related to the outcomes of preclinical and clinical studies, risks related to regulatory approvals, delays in commencement of preclinical and clinical studies, and costs associated with internal development and in-licensing activities. These and other risks and uncertainties are described more fully in Ardea's most recently filed SEC documents, including its Annual Report on Form 10-K and Quarterly Reports on Form 10-Q, under the headings "Risk Factors." All forward-looking statements contained in this press release speak only as of the date on which they were made. Ardea undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.


'/>"/>
SOURCE Ardea Biosciences, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Ardea Biosciences Presents Preclinical Data Demonstrating Favorable Resistance Profiles for Non-Nucleoside Reverse Transcriptase Inhibitors for the Treatment of Human Immunodeficiency Virus
2. Ardea Biosciences, Inc. Announces New Clinical Development Program Directed Toward the Treatment of Gout
3. Ardea Biosciences Lead MEK Inhibitor, RDEA119, to Enter Human Clinical Trials in Advanced Cancer Patients
4. Ardea Biosciences, Inc. Presents Results of Phase 1 Studies of RDEA806, a Novel NNRTI for HIV, at 47th ICAAC
5. Ardea Biosciences, Inc. Announces Completion of Phase 1 Clinical Trials of Novel Investigational HIV Drug RDEA806
6. Sangamo BioSciences Reports 2007 Fourth Quarter and Year-End Financial Results
7. Neurocrine Biosciences Reports Fourth Quarter and Year-End 2007 Results
8. CeloNova BioSciences Introduces a New Class of Coronary Stent: The CATANIA(TM) Coronary Stent System with NanoThin Polyzene(R)-F
9. CeloNova BioSciences Announces Positive Results from European Study of Embozene(TM) Microspheres for Treatment of Uterine Fibroids
10. Epiphany Biosciences Reports Initiation of Phase 2 Study of Valomaciclovir for the Treatment of Acute Infectious Mononucleosis
11. Sangamo BioSciences Announces Completion of Enrollment of Phase 2 Clinical Trial of ZFP Therapeutic for Diabetic Neuropathy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/28/2014)... QC , Nov. 28, 2014 /CNW Telbec/ - Ergoresearch ... and known under the « Équilibre, orthèses et ... Ended on September 30, 2014. All dollar amounts in the ... for the first quarter of fiscal year 2015 ended this ... by 2,1 % compared to revenues of $ 4 227 942 ...
(Date:11/28/2014)... LOS ANGELES , Nov. 28, 2014 According ... Americans over the course of their lifetime. For many, these ... chronic pain that is caused by a variety of factors. ... disc, surgery may be the best option. While there are ... Laser Discectomy performed by Seyed M. Rezaian , M.D., ...
(Date:11/28/2014)... Nov. 28, 2014  Valeant Pharmaceuticals International, Inc. ... announced that its wholly owned subsidiary, Valeant Pharmaceuticals ... of its outstanding 6.875% Senior Notes due 2018, ... on December 29, 2014 and has mailed an ... the redemption, approximately US$500 million aggregate principal amount ...
Breaking Medicine Technology:First Quarter Results fiscal year ended September 30, 2015 - Ergoresearch reports its results for the quarter ended September 30, 2014. 2First Quarter Results fiscal year ended September 30, 2015 - Ergoresearch reports its results for the quarter ended September 30, 2014. 3First Quarter Results fiscal year ended September 30, 2015 - Ergoresearch reports its results for the quarter ended September 30, 2014. 44 Advantages of Laser Back Surgery When Fixing a Herniated Disk 2Valeant Announces Redemption of US$445.0 Million Aggregate Principal Amount of its Outstanding 6.875% Senior Notes due 2018 2
... fewer products in the pipeline and more at the ... commercial life of mature brands are critical to today,s ... as many as 10 years and billions of dollars ... To help biopharmaceutical companies more effectively ...
... Mass., Feb. 24, 2012  Haemonetics Corporation (NYSE: HAE ... Company effective March 5, 2012 as Vice President of ... ) Mr. Helsel, age 48, was with ... was Vice President of Operations for the Surgical Solutions ...
Cached Medicine Technology:Report Delivers ROI Analysis on Key Lifecycle Management Strategies Utilized by the Pharmaceutical Industry 2Dave Helsel Joins Haemonetics as Vice President of Global Manufacturing 2
(Date:11/28/2014)... York, NY (PRWEB) November 28, 2014 ... physical therapy techniques such as Dynamic Neuromuscular Stabilization, ... and gait/motion analysis. After moving to upgraded facilities ... and running clinic. Now, owner Dr. Lev Kalika ... performance and injury prevention lab in the country. ...
(Date:11/28/2014)... Agein.com, the Internet’s premier anti-aging web site focusing ... foremost experts in the industry, is releasing its top diet ... , “The official start of winter is still three weeks ... with an icy blast. After one of the worst winters ... usher in another brutal winter,” says Dr. Kevin J. McLaughlin, ...
(Date:11/28/2014)... Junk-A-Car ( http://www.junkacar.com ), one of the ... to help drivers, especially those in and around the ... areas deal with the especially harsh winter weather that ... the country. , With the high number of reported ... crashed and junk cars, Junk-A-Car is voluntarily ...
(Date:11/28/2014)... Mequon, Wisconsin (PRWEB) November 28, 2014 ... facial plastic surgeons , announced the expansion of Quintessa ... new center will be located at W307 N1497 Golf ... 2015. , According to Dr. Campbell, the new Delafield ... non-surgical procedures for patients, including: Botox, filler ...
(Date:11/28/2014)... 2014 Secura Consultants, based in ... marketing organizations in the country focused on delivering ... marketplace. Secura Consultants is proud to offer complimentary ... Group, a leading global financial company. , Many ... the ownership interest comes the need for business ...
Breaking Medicine News(10 mins):Health News:New York Dynamic Neuromuscular Rehabilitation Opens Nation's Most Advanced Movement Performance and Injury Prevention Lab 2Health News:New York Dynamic Neuromuscular Rehabilitation Opens Nation's Most Advanced Movement Performance and Injury Prevention Lab 3Health News:Agein Corporation, a Leading Anti-Aging Company, Releases Top Diet and Personal Care Tips for Preventing Dry Skin this Season 2Health News:Junk-A-Car Expanding Service to Assist U.S. Car Owners That May be Affected by Severe Winter Storms 2Health News:Dr. Andrew Campbell to Expand Quintessa Aesthetic Center into Delafield 2Health News:Secura Consultants Offers Complimentary Buy-Sell Agreement Reviews 2
... -- Some women who inherit the BRCA1 or BRCA2 breast ... with breast cancer nearly a decade earlier than those who ... Researchers examined the family trees of 128 breast or ... determine the origins of the patients, cancer genes. "No ...
... around the world are reporting they are burned out and ... Pennsylvania School of Nursing,s Center for Health Outcomes and Policy ... Between 20 to 60 percent of nurses reported ... International Journal for Quality in Health Care , which ...
... of South American songbirds completed by the Department of ... Natural History, has discovered these birds differ dramatically in ... which indicates they are on the road to becoming ... show that species could change, that they were not ...
... Copenhagen have explored the active principles of a Danish mushroom ... particularly toxic towards cancer cells. The goal is to synthesise ... in future drug development. Asia has a long ... products. Many substances found in fungi are today registered as ...
... INDIANAPOLIS -- The health care system in the United States ... to the bedside, how to ensure more equitable use of ... how to pay for that care. The 10th ... of the journal Medical Care tackles key conceptual ...
... Over the past quarter century in Australia, cancer incidence rates ... are some of the findings of a recent study published ... Compared with any other disease group, cancer has ... two Australians developing cancer and one in five dying from ...
Cached Medicine News:Health News:Family Tree May Affect Diagnosis Age in Some Breast Cancers 2Health News:To keep nurses, improve their work environments 2Health News:Danish mushroom inspires cancer researchers 2Health News:Danish mushroom inspires cancer researchers 3Health News:Journal supplement presents strategies for introducing health care delivery innovation 2Health News:Study sheds light on cancer burden in Australia 2
... Aerosol Resistant Tips offer a safe alternative ... are designed for applications such as PCR(a), ... addition, ART Tips are excellent for tissue ... studies. ART Tips prevent aerosol contaminants and ...
... LBP Processor is a primary component of ... accessioning, processing, sampling, and slide preparation ... The MonoPrep LBP Processor produces high-quality sample ... broad range of cytology specimen types. It ...
... Like all Gilson disposable ... in a sterilized version. Each ... in medical device-quality plastic to ... Sterilization is guaranteed by the ...
200 L, Racked, Pre-sterilized, 96 tips/rack Recommended for 20, 25, 50, 100 and 200 L pipettes. Can also be used with 300 L pipettes when pipetting 200 L or less....
Medicine Products: